Articles related to MIGRAINES/HEADACHES

Explore the findings of a retrospective study examining treatment persistence in migraine patients using CGRP mAb therapies or Botox – the results may surprise you.

FDA’s New Approval of Atogepant for Chronic Migraine Prevention is a Breakthrough in Migraine Management A promising breakthrough in migraine management, the FDA’s new approval of atogepant tablets, brings renewed hope for chronic migraine sufferers. According to AbbVie, this endorsement allows the use of atogepant (Qulipta) in the prevention of chronic migraines in adults. Atogepant stands out as the first oral calcitonin gene-related peptide (CGRP) receptor antagonist to receive dual approval for episodic and chronic migraines. It works by blocking CGRP, a molecule involved in transmitting pain signals. Chronic migraines, to clarify, involve enduring headaches for at least 15 days a month, with eight of those days associated with migraines. Before this, in September 2021, the FDA approved atogepant for treating episodic migraines. Patients can take the drug in 10 mg, 30 mg, and 60 mg dosages. The FDA recommends the 60 mg dose for chronic migraine patients. Peter McAllister, MD, from the New England Center for Neurology and Headache, noted that the FDA’s endorsement offers a new, convenient daily treatment for chronic migraine patients. The demonstrated efficacy and functional improvement of atogepant make it an appealing option for neurologists and headache specialists when devising treatment plans for patients. The […]

The Nerivio device is worn on the arm and uses painless electrical stimulation to activate peripheral nerves, thereby inducing a conditioned pain modulation response. It is controlled by a smartphone app and is recommended to be used every other day for migraine prevention.

Misunderstandings and misperceptions about migraine persist, leading to misdiagnosis and less-than-optimal management. In this video, migraine experts seek to update the primary care provider on the current understanding of the disease, and the role of gepants, ditans, triptans, calcitonin gene-related peptide antibodies, and other therapies.

This broad review of recent studies in women’s health topics aims to help the primary care physician in discussing and guiding therapy for women in topics from cardiovascular disease to pelvic pain. The review covers such questions as: How does migraine with aura affect CVD risk in women? How do you respond to patient questions about fracture risk and bisphosphonates? Are antidepressants safe for women who are considering pregnancy? Is gabapentin effective for chronic pelvic pain?

A total of 35 status migrainosus patients were enrolled; 30 of them were female, and the average age was 39. Before the drugs were given, everyone’s serum magnesium levels were normal. There were no ECG alterations found, and none of the patients experienced any severe side effects either during or right away following the infusion. In 15 patients, there was a positive effect; in 10, there was no effect; and in 10, there were no data.